RNA Therapeutics Patents: Leaders, Trends & White Space 2026
- Concentration is modest at the top. the leader holds 483 records, and the five largest assignees combined account for just 22.9% of all 5,254 records in scope.
- Filing has kept climbing, not stalled. records rose from 513 in 2021 to 556 in 2024, an 8% increase over that span, after peaking at 688 in 2022.
- Lipid nanoparticle delivery patents dominate citations. the five most-cited records in the dataset are all lipid/LNP formulation filings for nucleic acid delivery, some cited over a thousand times.
Filing growth compares 2021 (513 records) with 2024 (556) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 5,254 records in scope (CR5), not by the ranked leaders only.
What this dataset covers
The scope spans 5,254 published patent families filed between 2015 and the 2026 data cut-off, drawn from records that combine RNA therapeutics language with clinical or analytical terms such as sequence read, molecular target, expression level and dosage composition. That combination captures filings that go beyond bare RNA chemistry claims into applied therapeutic and diagnostic use, which is where most commercial activity in this field now sits. Publication lags filing by roughly 18 months, so the last one to two years in any trend chart will always look lighter than they will once the backlog clears.
The ranking below covers the 100 companies the data endpoint returns, not an arbitrary top list, and is counted in patent families rather than raw document counts so that aggressive continuation filing or multi-jurisdiction refiling does not distort who is actually active.
Filing trends and technology composition
Two views of the same 5,254-record dataset: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
Filing trend, 2017-2026
Annual filings rose from 248 in 2017 to a peak of 688 in 2022, then eased before the 2021-2024 window closed at 556 — an 8% increase over three years. The 2025 and 2026 figures are still filling in as publications catch up with filing dates, so they should not be read as a slowdown.
Technology composition by IPC subclass
A61K (medicinal preparations) touches 69.4% of the 5,254 records and C12N (microorganisms and genetic engineering) touches 62.7%, confirming that most filings combine a formulation claim with a genetic-engineering claim. Because records can carry multiple IPC codes, these shares add up to well over 100% and should be read individually, not summed.
Shares are the percentage of the 5,254 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on RNA Therapeutics Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about rna therapeutics patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in the field
US20240392297A1 — RNA therapeutics and methods of use thereof
ADAR activating RNA, RNA therapeutics comprising an ADAR activating RNA and methods of using same.Filed by Eli Lilly and Company, published 2024-11-28, this record sits in the RNA-editing branch of the field rather than the delivery-formulation branch that dominates the citation table.
View full filing| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2017075531A1 | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | 1,065 |
| 2 | WO2015199952A1 | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | 947 |
| 3 | WO2017117528A1 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | 679 |
| 4 | WO2017004143A1 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | 584 |
| 5 | WO2018081480A1 | Lipid nanoparticle formulations | 545 |
| 6 | WO2014093924A1 | Modified nucleic acid molecules and uses thereof | 423 |
| 7 | US20150376115A1 | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | 416 |
| 8 | US20160376224A1 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | 321 |
| 9 | US20170119904A1 | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | 310 |
| 10 | WO2015062738A1 | Modified RNA with decreased immunostimulatory properties | 300 |
All five of the most-cited records in this dataset are lipid or lipid nanoparticle formulation patents for nucleic acid delivery, not RNA sequence claims themselves — a sign that delivery chemistry, not the payload, is where the earliest foundational IP was staked out.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing decisions
Three patterns stand out once the ranking, the trend and the citation table are read together.
No single assignee controls the field
The leader holds 483 records out of 5,254, and even the combined top five reach only 22.9% of all records in scope. Tenth place still holds 88 records, which points to a long tail of active filers rather than a field locked up by two or three incumbents.
Filing is still climbing, on the complete years
Records grew from 513 in 2021 to 556 in 2024, an 8% increase over that span, with a peak of 688 in 2022 in between. Treat 2025 and 2026 figures as incomplete rather than as evidence of a downturn.
Delivery chemistry, not payload, holds the oldest foundational claims
All five of the most-cited records are lipid or lipid nanoparticle formulation filings for nucleic acid delivery. Citation counts favour older records inside any searched corpus, so this reflects influence built up over time rather than which claims matter most to file around today.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to rna therapeutics patent landscape, with the prior art for and against each one.
Who is filing, and where the gaps sit
The ranked leaders combine large biopharma, dedicated RNA-delivery specialists and academic research institutes, with several recent years showing declining filing counts even among the most active names.
A clear leader without a runaway lead
The top-ranked assignee holds 483 records, well ahead of fifth place at 137, but the combined top five still cover only 22.9% of all 5,254 records in scope — leaving most of the field to companies and institutes outside the top ranks.
Even the most active names slowed in the latest year
Every assignee tracked for recent-year momentum shows a year-over-year decline in the latest year, from a smaller drop at the more active filer down to an 84% drop at another. Given the roughly 18-month publication lag, some of this is filings still working through the pipeline rather than a genuine pullback.
Academic-institute pairings anchor the strongest collaborations
The strongest co-assignee relationships in the dataset link a national health research institute with university and biotech partners, each pairing appearing on 73 shared filings, ahead of a pharma-university pairing at 25. This pattern suggests institute-led consortium filing rather than single-company R&D pipelines.
| Assignee | Recent year | YoY |
|---|---|---|
| Flagship Pioneering Innovations VII LLC | 11 | -31% |
| Acuitas Therapeutics Inc | 6 | -84% |
| Novartis AG | 2 | -78% |
| Generation Bio Co | 1 | -80% |
| The Board of Trustees of the Leland Stanford Junior University | 1 | -50% |
| Flagship Pioneering Innovations V Inc | 1 | -50% |
| Akamis Bio Ltd | 0 | -100% |
| Duke University | 0 | -100% |
Where to take this analysis
The ranking and trend data point to specific next steps depending on whether the goal is freedom-to-operate, portfolio strategy or scouting.
Check freedom-to-operate on delivery chemistry
Lipid and lipid nanoparticle formulation claims carry the heaviest citation weight in this dataset, so any program relying on LNP delivery should map its formulation against the highest-cited records before committing to a chemistry.
Run a freedom-to-operate checkTrack momentum among mid-tier filers
With the top five holding only 22.9% of records, competitive shifts are as likely to come from outside the ranked leaders as from within them. Watching filing counts below the top ten catches emerging entrants earlier.
Set up assignee monitoringProbe the under-claimed branches
RNA editing, circular RNA stability and non-LNP delivery vehicles show thinner filing density than the core formulation classes, which can mean either genuine white space or claims not yet indexed under these search terms.
Explore white space in EurekaCommon questions about RNA therapeutics patents
The dataset's top-ranked assignee holds 483 of the 5,254 records in scope, notably ahead of fifth place at 137 and tenth place at 88. However, the combined top five account for only 22.9% of all records, so no single company controls the field. The remainder is spread across a long tail of pharma companies, dedicated RNA-delivery specialists and academic research institutes.
Yes, on the years that are complete enough to judge. Filings rose from 513 records in 2021 to 556 in 2024, an 8% increase over that span, with a peak of 688 in 2022. Figures for 2025 and 2026 look lower only because publication typically lags filing by around 18 months, not because activity has slowed.
Medicinal preparation claims under IPC class A61K appear in 69.4% of the 5,254 records, and genetic engineering claims under C12N appear in 62.7%, meaning most filings pair a formulation claim with a genetic-engineering claim. Therapeutic activity claims (A61P) and peptide and protein claims (C07K) follow at 24.5% and 21.7% respectively. Because a single record can carry several IPC codes, these percentages overlap rather than summing to 100%.
The five most-cited records in this dataset are all lipid or lipid nanoparticle formulation patents for nucleic acid delivery, led by a filing cited 1,065 times. This concentration reflects how foundational LNP delivery chemistry became for the whole field, since citation counts accumulate over time and favour earlier-filed records. It does not mean delivery chemistry is where current filing activity is heaviest, only where the earliest influential claims were staked.
Branches such as ADAR-mediated RNA editing, circular RNA stability engineering, self-amplifying RNA dosing regimens and non-LNP extrahepatic delivery vehicles show comparatively thinner filing density than the core formulation and delivery classes. That thinness can mean genuine open claim space, but it can also mean the technology is emerging or filed under different search terms, so it is worth checking each branch individually before assuming it is unclaimed.
Research RNA Therapeutics Patent Landscape in depth with Eureka
Go past this page: query the whole rna therapeutics patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.